©2022 Stanford Medicine
Pharmacogenomic Analysis in Pediatric Acute Lymphoblastic Leukemia
Recruiting
Trial ID: NCT04770922
Purpose
This is a retrospective biobank study evaluating the impact of novel genetic variants in a
population of 6-mercaptopurine treated pediatric acute lymphoblastic leukemia patients.
Official Title
Pharmacogenomic Analysis of 6-mercaptopurine in Pediatric Acute Lymphoblastic Leukemia
Stanford Investigator(s)
Stephanie Melissa Smith
Instructor, Pediatrics - Hematology & Oncology
Eligibility
Inclusion Criteria:
- Pediatric acute lymphoblastic leukemia (ALL) subjects
- Received 6-mercaptopurine
- Available biobank (bone marrow or blood) sample(s) from which deoxyribonucleic acid
(DNA) can be extracted
- White blood cell (WBC) levels
Exclusion Criteria:
- Pediatric ALL subjects who did NOT receive 6-mercaptopurine
- No biobank sample
- No WBC level
Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305